1-45332941-C-G

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate

The NM_001048174.2(MUTYH):​c.397G>C​(p.Asp133His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000613 in 1,614,150 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D133V) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.00011 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000056 ( 0 hom. )

Consequence

MUTYH
NM_001048174.2 missense

Scores

2
4
13

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:11B:1

Conservation

PhyloP100: 2.65
Variant links:
Genes affected
MUTYH (HGNC:7527): (mutY DNA glycosylase) This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2017]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 0 ACMG points.

PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.09248924).

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
MUTYHNM_001128425.2 linkuse as main transcriptc.481G>C p.Asp161His missense_variant 6/16 ENST00000710952.2
MUTYHNM_001048174.2 linkuse as main transcriptc.397G>C p.Asp133His missense_variant 6/16 ENST00000456914.7

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
MUTYHENST00000710952.2 linkuse as main transcriptc.481G>C p.Asp161His missense_variant 6/16 NM_001128425.2
MUTYHENST00000456914.7 linkuse as main transcriptc.397G>C p.Asp133His missense_variant 6/161 NM_001048174.2 A1Q9UIF7-6

Frequencies

GnomAD3 genomes
AF:
0.000112
AC:
17
AN:
152196
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000724
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000196
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000132
Gnomad OTH
AF:
0.000955
GnomAD3 exomes
AF:
0.0000998
AC:
25
AN:
250434
Hom.:
0
AF XY:
0.0000517
AC XY:
7
AN XY:
135366
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.000550
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000354
Gnomad OTH exome
AF:
0.000327
GnomAD4 exome
AF:
0.0000561
AC:
82
AN:
1461836
Hom.:
0
Cov.:
35
AF XY:
0.0000454
AC XY:
33
AN XY:
727222
show subpopulations
Gnomad4 AFR exome
AF:
0.0000299
Gnomad4 AMR exome
AF:
0.000537
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.0000396
Gnomad4 OTH exome
AF:
0.000215
GnomAD4 genome
AF:
0.000112
AC:
17
AN:
152314
Hom.:
0
Cov.:
32
AF XY:
0.000121
AC XY:
9
AN XY:
74474
show subpopulations
Gnomad4 AFR
AF:
0.0000722
Gnomad4 AMR
AF:
0.000196
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000132
Gnomad4 OTH
AF:
0.000945
Alfa
AF:
0.0000282
Hom.:
0
Bravo
AF:
0.0000793
ExAC
AF:
0.000107
AC:
13
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:11Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Familial adenomatous polyposis 2 Uncertain:5
Uncertain significance, criteria provided, single submitterclinical testingLaboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert EinsteinSep 26, 2021ACMG classification criteria: PS4 supporting, PM2 moderate -
Uncertain significance, criteria provided, single submitterclinical testingCounsylDec 30, 2015- -
Uncertain significance, criteria provided, single submitterclinical testingInvitaeJan 09, 2024This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 161 of the MUTYH protein (p.Asp161His). This variant is present in population databases (rs564930066, gnomAD 0.05%). This missense change has been observed in individual(s) with breast cancer, clinical features of MUTYH-associated polyposis (MAP), and/or endometrial cancer (PMID: 21424714, 25980754, 27443514, 30093976, 35264596; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 140814). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingMendelicsJul 02, 2018- -
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsMar 17, 2024- -
Hereditary cancer-predisposing syndrome Pathogenic:1Uncertain:1Benign:1
Likely pathogenic, criteria provided, single submitterclinical testingAmbry GeneticsJan 17, 2024The c.481G>C variant (also known as p.D161H), located in coding exon 6 of the MUTYH gene, results from a G to C substitution at nucleotide position 481. The aspartic acid at codon 161 is replaced by histidine, an amino acid with similar properties. This variant has been detected in conjunction with a MUTYH pathogenic variant or as homozygous in multiple unrelated individuals with clinical features of MUTYH-associated disease; however, the phase of the variants from the compound heterozygous cases is unknown (Ambry internal data). This variant was also reported in conjunction with MUTYH p.P405L in a patient with colorectal cancer (Weren RD et al. Nat Genet, 2015 Jun;47:668-71). This alteration has also been reported in prostate and breast cancer cohorts who underwent hereditary multigene panel testing (Chan GHJ et al. Oncotarget, 2018 Jul;9:30649-30660; Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. However, RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). This amino acid position is not well conserved in available vertebrate species. In addition, as a missense substitution this alteration is predicted to be tolerated by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Sep 10, 2021- -
Likely benign, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthMar 21, 2016- -
not specified Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingWomen's Health and Genetics/Laboratory Corporation of America, LabCorpAug 18, 2022Variant summary: MUTYH c.481G>C (p.Asp161His) results in a non-conservative amino acid change located in the HhH-GPD domain (IPR003265) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0001 in 250434 control chromosomes, predominantly at a frequency of 0.00055 within the Latino subpopulation in the gnomAD database. This frequency is not higher than estimated for a pathogenic variant in MUTYH causing MUTYH-Associated Polyposis (0.0001 vs 0.0046), allowing no conclusion about variant significance. c.481G>C has been reported in the literature in individuals affected prostate cancer (Chan_2018), suspected lynch syndrome (Yurgelun_2015) without strong evidence for causality. Variant has been reported in a patient with colorectal cancer and a second pathogenic allele p.Y179C (Pitroski_2011). Additionally, the variant has also been reported in breast cancer cases and controls (Dorling_2021). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Ten clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified the variant as VUS (n=9) and likely benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Uncertain significance, criteria provided, single submitterclinical testingCenter for Genomic Medicine, Rigshospitalet, Copenhagen University HospitalJul 31, 2024- -
not provided Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingGeneDxJun 13, 2022In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25938944, 21777424, 25980754, 29684080, 30093976) -
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoOct 28, 2022The frequency of this variant in the general population, 0.00054 (19/35412 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with colorectal cancer and/or polyposis (PMIDs: 25938944 (2015) and 25980754 (2015)), Cowden Syndrome (PMID: 29684080 (2018)), endometrial cancer (PMID: 27443514 (2016)), prostate cancer (PMID: 30093976 (2018)), breast cancer (PMID: 33471991 (2021), see also LOVD (https://databases.lovd.nl/shared/variants/MUTYH)) and pediatric astrocytoma (PMID: 31970404 (2020)). Additionally, the variant has been reported in healthy individuals with no personal or family history of cancer (PMIDs: 21777424 (2011) and 33471991 (2021), see also LOVD (https://databases.lovd.nl/shared/variants/MUTYH)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
MUTYH-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingPreventionGenetics, part of Exact SciencesNov 20, 2023The MUTYH c.481G>C variant is predicted to result in the amino acid substitution p.Asp161His. This variant was reported in individuals with suspected Lynch syndrome, kidney renal clear cell carcinoma, prostate cancer, or breast cancer (Table S2, Yurgelun et al. 2015. PubMed ID: 25980754; Table S7, Yehia et al. 2018. PubMed ID: 29684080; Table S2, Chan et al. 2018. PubMed ID: 30093976; Table S3, Guindalini et al. 2022. PubMed ID: 35264596). This variant was also reported along with an established pathogenic MUTYH variant in an individual with colorectal cancer (Pitroski et al. 2011. PubMed ID: 21424714). This variant is reported in 0.054% of alleles in individuals of Latino descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-45798613-C-G) and has conflicting interpretations of pathogenicity in ClinVar ranging from likely benign to uncertain (http://www.ncbi.nlm.nih.gov/clinvar/variation/140814). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.15
BayesDel_addAF
Benign
-0.21
T
BayesDel_noAF
Benign
-0.20
CADD
Uncertain
24
DANN
Benign
0.96
DEOGEN2
Benign
0.15
.;.;.;.;.;T;.;.;.;T;T
Eigen
Uncertain
0.31
Eigen_PC
Uncertain
0.38
FATHMM_MKL
Pathogenic
0.97
D
LIST_S2
Pathogenic
0.98
.;D;.;D;D;D;D;D;D;D;D
M_CAP
Benign
0.059
D
MetaRNN
Benign
0.092
T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Uncertain
0.26
D
MutationAssessor
Benign
1.6
.;.;.;.;.;L;.;.;.;.;.
MutationTaster
Benign
1.0
D;D;D;D;D;D;D;D;D;D;D;D;D;D
PrimateAI
Benign
0.43
T
PROVEAN
Benign
-1.6
N;N;N;N;N;N;N;N;N;N;N
REVEL
Uncertain
0.35
Sift
Benign
0.21
T;T;T;T;T;T;T;T;T;T;T
Sift4G
Benign
0.19
T;T;T;T;T;T;T;T;T;T;T
Polyphen
0.76, 0.53, 0.58
.;.;.;.;.;P;P;.;P;.;.
Vest4
0.30
MVP
0.94
MPC
0.18
ClinPred
0.058
T
GERP RS
5.2
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
Varity_R
0.29
gMVP
0.62

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs564930066; hg19: chr1-45798613; API